Similarly, a recent trial of first-line treatment with cetuximab in combination with FOLFIRI showed that such treatment reduced the risk of disease progression compared with FOLFIRI alone in patients with KRAS wild-type tumours [8]. Here, KRAS is linked to neoplasm.